In 1990, Don Sawyer entered industry like many others do: as a sales representative.
DON SAWYER
Vice President, Managed Markets, AstraZeneca
In 1990, Don Sawyer entered industry like many others do: as a sales representative. But unlike most, he quickly gained prominence in industry for being one of the driving forces in developing AstraZeneca's novel strategic approach to the new Medicare Part D Benefit in 2006. As a result, today more than 90 percent of those in Medicare now have comprehensive drug coverage from Part D.
Make no mistake, this achievement was a "huge team effort," notes Sawyer, who believes that the foundation of great leadership lies in trust and confidence—two qualities Howard Swain, one of Sawyer's first district managers at Pfizer, observed early on when "Don's quick wit and great personality" set him apart from other prospective job candidates. "Despite being short on experience, Don was very long on the characteristics and qualities we and other managers thought would make him very successful in the pharma industry—or any other industry," Swain says.
And his prediction was right.
Currently, Sawyer leads the way for AstraZeneca in developing and implementing both brand and contract strategy for managed markets across the company's portfolio for the US business, in addition to running its US managed markets sales organization. And there's no stopping the 41-year-old former athlete and sports enthusiast who hopes that in 10 years he will be part of a "tremendous leadership team that will lead AstraZeneca through this period of tremendous industry change."
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.